Wyeth Ends Bifeprunox For Schizophrenia Development Deal With Solvay
This article was originally published in The Pink Sheet Daily
Executive Summary
Wyeth decides drug candidate has inadequate commercial value for both companies to share, firm tells "The Pink Sheet" DAILY.